grepafloxacin
Sign in to saveGrepafloxacin (trade name Raxar, Glaxo Wellcome) was an oral broad-spectrum fluoroquinolone antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn worldwide from markets in 1999, due to the drug's potential to cause a potentially fatal cardiac arrhythmia.
Chemical data
- Formula
- C19H22FN3O3
- Molecular weight
- 359.4 g/mol
- IUPAC name
- 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
via PubChem
Research
345 papers- Grepafloxacin.Drugs · 1997
- Pharmacokinetics of grepafloxacin.The Journal of antimicrobial chemotherapy · 1997
- Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.Clinical therapeutics · 1999
- Grepafloxacin--focus on respiratory infections.The Journal of antimicrobial chemotherapy · 1997
- Antibacterial activity of grepafloxacin.The Journal of antimicrobial chemotherapy · 1997
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +359.16452
Show 1 more fact
- P366
- medication
via Wikidata · CC0
Article
5 sectionsContents
- Clinical uses
- Synthesis
- Stereochemistry
- See also
- References
Grepafloxacin (trade name Raxar, Glaxo Wellcome) was an oral broad-spectrum fluoroquinolone antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn worldwide from markets in 1999, due to the drug's potential to cause a potentially fatal cardiac arrhythmia.
== Clinical uses == Grepafloxacin was used for treating exacerbations of chronic bronchitis caused by susceptible bacteria (e.g. Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis), community-acquired pneumonia (including those, in addition to the above germs, caused by Mycoplasma pneumoniae) gonorrhea and non-gonococcal urethritis and cervicitis (for example caused by Chlamydia trachomatis or Ureaplasma urealyticum).